https://www.nasdaq.com/press-release/athira-pharma-provides-2022-pipeline-outlook-2022-01-05
https://www.nasdaq.com/press-release/athira-pharma-reports-third-quarter-2021-financial-results-and-business-update-2021
https://www.nasdaq.com/press-release/athira-pharma-presents-overview-and-update-from-act-ad-and-lift-ad-trials-of-ath-1017
https://www.nasdaq.com/press-release/athira-pharma-to-present-at-upcoming-investor-conferences-2021-11-08
https://www.nasdaq.com/press-release/athira-pharma-to-host-educational-webinar-on-the-clinical-applications-of-erp-p300
https://www.nasdaq.com/press-release/athira-pharma-announces-completion-of-enrollment-in-phase-2-act-ad-trial-evaluating
https://www.nasdaq.com/press-release/athira-pharma-announces-leadership-changes-mark-litton-ph.d.-m.b.a.-named-president
https://www.nasdaq.com/press-release/athira-pharma-to-present-updates-from-phase-2-3-trials-of-ath-1017-at-the-2021
https://www.nasdaq.com/press-release/athira-pharma-to-present-on-erp-p300-as-a-direct-functional-non-invasive-biomarker-at
https://www.nasdaq.com/press-release/athira-pharma-reports-second-quarter-2021-financial-results-and-business-update-2021
https://www.nasdaq.com/press-release/athira-pharma-mourns-the-loss-of-chair-of-board-of-directors-tadataka-yamada-m.d.
https://www.nasdaq.com/press-release/abraham-fruchter-twersky-llp-announces-the-filing-of-a-class-action-lawsuit-on-0
https://www.nasdaq.com/press-release/athira-pharma-to-present-ath-1017-phase-1-translational-data-at-the-alzheimers
https://www.nasdaq.com/press-release/athira-pharma-announces-initiation-of-open-label-extension-study-for-lift-ad-and-act
https://www.nasdaq.com/press-release/washington-state-university-to-review-claims-of-research-misconduct-2021-06-18
https://www.nasdaq.com/press-release/athira-pharma-chief-operating-officer-mark-litton-assumes-day-to-day-leadership
https://www.nasdaq.com/press-release/athira-pharma-appoints-rachel-lenington-as-chief-technology-officer-head-of-product
https://www.nasdaq.com/press-release/athira-pharma-to-present-at-upcoming-investor-conferences-2021-06-09
https://www.nasdaq.com/press-release/athira-pharma-appoints-mark-worthington-as-general-counsel-2021-06-01
https://www.nasdaq.com/press-release/athira-pharma-to-present-at-upcoming-investor-conferences-2021-05-26
https://www.nasdaq.com/press-release/athira-pharma-reports-first-quarter-2021-financial-results-and-provides-business
https://www.nasdaq.com/press-release/athira-pharma-to-participate-in-panel-discussion-at-sachs-4th-annual-neuroscience
https://www.nasdaq.com/press-release/athira-pharma-to-host-educational-webinar-on-targeting-hgf-met%3a-a-naturally-occurring
https://www.nasdaq.com/press-release/athira-pharma-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/athira-pharma-to-present-at-stifels-3rd-annual-cns-conference-2021-03-24
https://www.nasdaq.com/press-release/athira-pharma-to-participate-in-panel-and-corporate-presentations-at-life-science
https://www.nasdaq.com/press-release/athira-pharma-announces-appointment-of-barbara-kosacz-to-its-board-of-directors-2021
https://www.nasdaq.com/press-release/athira-pharma-to-present-at-h.c.-wainwright-co.-global-life-sciences-conference-2021
https://www.nasdaq.com/press-release/athira-pharma-announces-exercise-of-underwriters-option-to-purchase-additional-shares
https://www.nasdaq.com/press-release/athira-pharma-announces-pricing-of-public-offering-of-common-stock-2021-01-20
https://www.nasdaq.com/press-release/athira-pharma-announces-proposed-public-offering-of-common-stock-2021-01-19
https://www.nasdaq.com/press-release/athira-pharma-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-2021-01
https://www.nasdaq.com/press-release/athira-pharma-announces-appointment-of-kelly-a.-romano-to-its-board-of-directors-2020
https://www.nasdaq.com/press-release/athira-pharma-awarded-%2415-million-grant-from-national-institute-on-aging-to-support
https://www.nasdaq.com/press-release/athira-pharma-announces-initiation-of-patient-dosing-for-act-ad-clinical-trial-of-ath
https://www.nasdaq.com/press-release/athira-pharma-reports-third-quarter-2020-financial-results-and-provides-business
https://www.nasdaq.com/press-release/athira-pharma-to-present-at-upcoming-november-investor-conferences-2020-11-10
https://www.nasdaq.com/press-release/athira-pharma-to-host-educational-webinar-on-the-predictive-nature-of-p300-to
https://www.nasdaq.com/press-release/lumen-bioscience-announces-appointment-of-dr.-mark-litton-to-board-of-directors-2020
https://www.nasdaq.com/press-release/athira-pharma-announces-initiation-of-patient-dosing-for-the-lift-ad-study-a-phase-2
